# EDGAR Filing Document

**Accession Number:** 0000939930
**File Stem:** 0000939930-25-000053
**Filing Date:** 2025-8
**Character Count:** 129087
**Document Hash:** 77d9147fe4c8e1046ea2b2533dc8af1c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000939930-25-000053.hdr.sgml**: 20250806

**ACCESSION NUMBER**: 0000939930-25-000053

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 88

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250806

**DATE AS OF CHANGE**: 20250806

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PYXUS INTERNATIONAL, INC.
- **CENTRAL INDEX KEY:** 0000939930
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-FARM PRODUCT RAW MATERIALS [5150]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 852386250
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-25734
- **FILM NUMBER:** 251187368

**BUSINESS ADDRESS:**
- **STREET 1:** 6001 HOSPITALITY COURT
- **STREET 2:** SUITE 100
- **CITY:** MORRISVILLE
- **STATE:** NC
- **ZIP:** 27560-2009
- **BUSINESS PHONE:** 9193794300

**MAIL ADDRESS:**
- **STREET 1:** 6001 HOSPITALITY COURT
- **STREET 2:** SUITE 100
- **CITY:** MORRISVILLE
- **STATE:** NC
- **ZIP:** 27560-2009

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALLIANCE ONE INTERNATIONAL, INC.
- **DATE OF NAME CHANGE:** 20050516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DIMON INC
- **DATE OF NAME CHANGE:** 19950301

?xml version='1.0' encoding='ASCII'? pyx-20250630

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

**☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2025.**

**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _______ TO _______.**

---

| |
|:---|
| **000-25734** |
| (Commission File Number) |

---

![Image1.jpg](pyx-20250630_g1.jpg)

**Pyxus International, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Virginia** | **Virginia** | **85-2386250** |
| (State or other jurisdiction of incorporation) | (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) |
| **6001 Hospitality Court, Suite 100** | **6001 Hospitality Court, Suite 100** | |
| **Morrisville,** | **North Carolina** | **27560** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Zip Code) |

---

**(919) 379-4300** 

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes **☒** No **☐**

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes **☒** No **☐**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer **☐** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Non-accelerated filer **☒**

Accelerated filer **☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

Smaller reporting company **☒** 

Emerging growth company **☐** 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. **☐**

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes **☐** No **☒**

Indicate by check mark if the registrant has filed all documents and reports required to be filed under Sections 12, 13, or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes **☒** No **☐**

As of July 31, 2025, the registrant had 24,607,791 shares outstanding of Common Stock (no par value).

------

---

| | | |
|:---|:---|:---|
| **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** |
| **Table of Contents** | **Table of Contents** | **Table of Contents** |
| | | **<u>Page Number</u>** |
| **<u>Part I</u>** | Financial Information | |
| Item 1. | Financial Statements (Unaudited) | |
| | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Operations](#i2474226e74764caf8765b48a7e12feb1_22)</u> | <u>[3](#i2474226e74764caf8765b48a7e12feb1_22)</u> |
| | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Comprehensive (Loss) Income](#i2474226e74764caf8765b48a7e12feb1_25)</u> | <u>[4](#i2474226e74764caf8765b48a7e12feb1_25)</u> |
| | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Balance Sheets](#i2474226e74764caf8765b48a7e12feb1_28)</u> | <u>[5](#i2474226e74764caf8765b48a7e12feb1_28)</u> |
| | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Stockholders' Equity](#i2474226e74764caf8765b48a7e12feb1_31)</u> | <u>[6](#i2474226e74764caf8765b48a7e12feb1_31)</u> |
| | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows](#i2474226e74764caf8765b48a7e12feb1_34)</u> | <u>[7](#i2474226e74764caf8765b48a7e12feb1_34)</u> |
| | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Condensed Consolidated Financial Statements](#i2474226e74764caf8765b48a7e12feb1_40)</u> | <u>[8](#i2474226e74764caf8765b48a7e12feb1_40)</u> |
| Item 2. | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i2474226e74764caf8765b48a7e12feb1_121)</u> | <u>[23](#i2474226e74764caf8765b48a7e12feb1_121)</u> |
| Item 3. | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i2474226e74764caf8765b48a7e12feb1_175)</u> | <u>[30](#i2474226e74764caf8765b48a7e12feb1_175)</u> |
| Item 4. | <u>[Controls and Procedures](#i2474226e74764caf8765b48a7e12feb1_178)</u> | <u>[31](#i2474226e74764caf8765b48a7e12feb1_178)</u> |
| **<u>Part II</u>** | Other Information | |
| Item 1. | <u>[Legal Proceedings](#i2474226e74764caf8765b48a7e12feb1_184)</u> | <u>[31](#i2474226e74764caf8765b48a7e12feb1_184)</u> |
| Item 1A. | <u>[Risk Factors](#i2474226e74764caf8765b48a7e12feb1_187)</u> | <u>[31](#i2474226e74764caf8765b48a7e12feb1_187)</u> |
| Item 2. | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i2474226e74764caf8765b48a7e12feb1_190)</u> | <u>[31](#i2474226e74764caf8765b48a7e12feb1_190)</u> |
| Item 5. | <u>[Other Information](#i2474226e74764caf8765b48a7e12feb1_199)</u> | <u>[32](#i2474226e74764caf8765b48a7e12feb1_199)</u> |
| Item 6. | <u>[Exhibits](#i2474226e74764caf8765b48a7e12feb1_202)</u> | <u>[32](#i2474226e74764caf8765b48a7e12feb1_202)</u> |
| | <u>[Signature](#i2474226e74764caf8765b48a7e12feb1_205)</u> | <u>[33](#i2474226e74764caf8765b48a7e12feb1_205)</u> |

---

------

**Part I. Financial Information**

**<u>Item 1. Financial Statements</u>**

---

| | | |
|:---|:---|:---|
| **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** |
| **Condensed Consolidated Statements of Operations** | **Condensed Consolidated Statements of Operations** | **Condensed Consolidated Statements of Operations** |
| *(Unaudited)* | *(Unaudited)* | *(Unaudited)* |
|  | Three Months Ended | Three Months Ended |
|  | June 30, | June 30, |
| *(in thousands, except per share data)* | 2025 | 2024 |
| Sales and other operating revenues | $508815 | $634855 |
| Cost of goods and services sold | 443189 | 551003 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 65626 | 83852 |
| Selling, general, and administrative expenses | 40369 | 40662 |
| Other expense, net | 4176 | 2630 |
| Restructuring and asset impairment charges | 81 | 103 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating income | 21000 | 40457 |
| Gain on debt retirement |  | 1323 |
| Interest expense, net | 29767 | 33272 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loss) income before income taxes and other items | (8767) | 8508 |
| Income tax expense | 5227 | 6119 |
| (Loss) income from unconsolidated affiliates, net | (1269) | 2563 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income | (15263) | 4952 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to noncontrolling interests | 562 | 310 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income attributable to Pyxus International, Inc. | $(15825) | $4642 |
| (Loss) earnings per share: |  |  |
| &nbsp;&nbsp;Basic | $(0.62) | $0.18 |
| &nbsp;&nbsp;Diluted | $(0.62) | $0.18 |
| Weighted average number of shares outstanding: |  |  |
| &nbsp;&nbsp;Basic | 25670 | 25461 |
| &nbsp;&nbsp;Diluted | 25670 | 25461 |
| *See "Notes to Condensed Consolidated Financial Statements"* | *See "Notes to Condensed Consolidated Financial Statements"* | *See "Notes to Condensed Consolidated Financial Statements"* |

---

------

---

| | | |
|:---|:---|:---|
| **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** |
| **Condensed Consolidated Statements of Comprehensive (Loss) Income** | **Condensed Consolidated Statements of Comprehensive (Loss) Income** | **Condensed Consolidated Statements of Comprehensive (Loss) Income** |
| *(Unaudited)* | *(Unaudited)* | *(Unaudited)* |
|  | Three Months Ended | Three Months Ended |
|  | June 30, | June 30, |
| *(in thousands)* | 2025 | 2024 |
| Net (loss) income | $(15263) | $4952 |
| Other comprehensive income (loss), net of tax: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | 2039 | 543 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flow hedges | 1457 | (2237) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss), net of tax | 3496 | (1694) |
| Total comprehensive (loss) income | (11767) | 3258 |
| Comprehensive income attributable to noncontrolling interests | 562 | 310 |
| &nbsp;&nbsp;&nbsp;&nbsp;Comprehensive (loss) income attributable to Pyxus International, Inc. | $(12329) | $2948 |
| *See "Notes to Condensed Consolidated Financial Statements"* | *See "Notes to Condensed Consolidated Financial Statements"* |  |

---

------

---

| | | | |
|:---|:---|:---|:---|
| **Pyxus International, Inc. and Subsidiaries**<br>**Condensed Consolidated Balance Sheets** <br>*(Unaudited)* | **Pyxus International, Inc. and Subsidiaries**<br>**Condensed Consolidated Balance Sheets** <br>*(Unaudited)* | **Pyxus International, Inc. and Subsidiaries**<br>**Condensed Consolidated Balance Sheets** <br>*(Unaudited)* | **Pyxus International, Inc. and Subsidiaries**<br>**Condensed Consolidated Balance Sheets** <br>*(Unaudited)* |
| *(in thousands)* | June 30, 2025 | June 30, 2024 | March 31, 2025 |
| **Assets** |  |  |  |
| Current assets |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $96437 | $82042 | $78254 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | 4945 | 7061 | 7290 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade receivables, net | 206607 | 209053 | 189239 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other receivables | 16683 | 17042 | 15040 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 1121788 | 1014527 | 761951 |
| &nbsp;&nbsp;&nbsp;&nbsp;Advances to tobacco suppliers, net | 61737 | 43863 | 30745 |
| &nbsp;&nbsp;&nbsp;&nbsp;Recoverable income taxes | 11670 | 4070 | 6616 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 50011 | 47270 | 47151 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 21123 | 17219 | 21874 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1591001 | 1442147 | 1158160 |
| Investments in unconsolidated affiliates | 95659 | 103818 | 96928 |
| Intangible assets, net | 27387 | 32728 | 28507 |
| Deferred income taxes, net | 13181 | 8947 | 13567 |
| Long-term recoverable income taxes | 4956 | 3985 | 5669 |
| Other noncurrent assets | 39315 | 33097 | 33094 |
| Right-of-use assets | 32033 | 33521 | 29742 |
| Property, plant, and equipment, net | 136993 | 134468 | 138176 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1940525 | $1792711 | $1503843 |
| **Liabilities and Stockholders' Equity** |  |  |  |
| Current liabilities |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Notes payable | $880925 | $679399 | $395030 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 124341 | 115312 | 132871 |
| &nbsp;&nbsp;&nbsp;&nbsp;Advances from customers | 87374 | 70985 | 135607 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 104162 | 99052 | 90912 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 10449 | 8706 | 11001 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating leases payable | 9565 | 7822 | 8514 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt |  | 20445 | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 1216816 | 1001721 | 773947 |
| Long-term taxes payable | 6195 | 5373 | 5187 |
| Long-term debt | 455091 | 531461 | 454850 |
| Deferred income taxes | 8902 | 6571 | 8818 |
| Liability for unrecognized tax benefits | 21935 | 19257 | 18635 |
| Long-term leases | 19541 | 22456 | 19584 |
| Pension, postretirement, and other long-term liabilities | 57805 | 52760 | 57052 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $1786285 | $1639599 | $1338073 |
| Commitments and contingencies |  |  |  |
| Stockholders' equity |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common Stock—no par value: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorized shares (250,000 for all periods) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issued and outstanding shares (24,608, 25,000 and 24,608) | $393136 | $392820 | $392899 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained deficit | (255950) | (250649) | (240125) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 10811 | 6092 | 7315 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity of Pyxus International, Inc. | 147997 | 148263 | 160089 |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interests | 6243 | 4849 | 5681 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 154240 | 153112 | 165770 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $1940525 | $1792711 | $1503843 |
| *See "Notes to Condensed Consolidated Financial Statements"* | *See "Notes to Condensed Consolidated Financial Statements"* | *See "Notes to Condensed Consolidated Financial Statements"* | *See "Notes to Condensed Consolidated Financial Statements"* |

---

------

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** |
| **Condensed Consolidated Statements of Stockholders' Equity** | **Condensed Consolidated Statements of Stockholders' Equity** | **Condensed Consolidated Statements of Stockholders' Equity** | **Condensed Consolidated Statements of Stockholders' Equity** | **Condensed Consolidated Statements of Stockholders' Equity** | **Condensed Consolidated Statements of Stockholders' Equity** | **Condensed Consolidated Statements of Stockholders' Equity** | **Condensed Consolidated Statements of Stockholders' Equity** |
| *(Unaudited)* | *(Unaudited)* | *(Unaudited)* | *(Unaudited)* | *(Unaudited)* | *(Unaudited)* | *(Unaudited)* | *(Unaudited)* |
|  | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. |  |  |
|  |  |  | Accumulated Other Comprehensive Income | Accumulated Other Comprehensive Income | Accumulated Other Comprehensive Income |  |  |
| *(in thousands)* | Common Stock | Retained <br>Deficit | Currency Translation Adjustment | Pensions,<br>Net of Tax | Derivatives, Net of Tax | Noncontrolling <br>Interests | Total Stockholders' Equity |
| Balance, March 31, 2025 | $392899 | $(240125) | $(6045) | $12516 | $844 | $5681 | $165770 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income |  | (15825) |  |  |  | 562 | (15263) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 237 |  |  |  |  |  | 237 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income, net of tax |  |  | 2039 |  | 1457 |  | 3496 |
| Balance, June 30, 2025 | $393136 | $(255950) | $(4006) | $12516 | $2301 | $6243 | $154240 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| Balance, March 31, 2024 | $389789 | $(255291) | $(5692) | $12766 | $712 | $4539 | $146823 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  | 4642 |  |  |  | 310 | 4952 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 3031 |  |  |  |  |  | 3031 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss), net of tax |  |  | 543 |  | (2237) |  | (1694) |
| Balance, June 30, 2024 | $392820 | $(250649) | $(5149) | $12766 | $(1525) | $4849 | $153112 |

---

*See "Notes to Condensed Consolidated Financial Statements"*

------

---

| | | |
|:---|:---|:---|
| **Pyxus International, Inc. and Subsidiaries**<br>**Condensed Consolidated Statements of Cash Flows** <br>*(Unaudited)* | **Pyxus International, Inc. and Subsidiaries**<br>**Condensed Consolidated Statements of Cash Flows** <br>*(Unaudited)* | **Pyxus International, Inc. and Subsidiaries**<br>**Condensed Consolidated Statements of Cash Flows** <br>*(Unaudited)* |
|  | Three Months Ended | Three Months Ended |
|  | June 30, | June 30, |
| *(in thousands)* | 2025 | 2024 |
| **Operating Activities:** |  |  |
| &nbsp;&nbsp;Net (loss) income | $(15263) | $4952 |
| &nbsp;&nbsp;Adjustments to reconcile net (loss) income to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5169 | 5127 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt amortization/interest | 2592 | 2828 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on debt retirement |  | (1323) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on foreign currency transactions | 7725 | 978 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 237 | 3031 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) income from unconsolidated affiliates, net of dividends | 1269 | (2563) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities, net |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade and other receivables | (52367) | (72392) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories and advances to tobacco suppliers | (388020) | (108015) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred items | 4529 | (899) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recoverable income taxes | (4477) | (622) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payables and accrued expenses | 393 | (64786) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advances from customers | (49806) | (18550) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | (2660) | 3883 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | (838) | 326 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other operating assets and liabilities | 2000 | (175) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | (5770) | (3976) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | $(495287) | $(252176) |
| **Investing Activities:** |  |  |
| &nbsp;&nbsp;Purchases of property, plant, and equipment | $(4279) | $(5097) |
| &nbsp;&nbsp;Collections from beneficial interests in securitized trade receivables | 41007 | 31741 |
| &nbsp;&nbsp;Other, net | 913 | 1304 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by investing activities | $37641 | $27948 |
| **Financing Activities:** |  |  |
| &nbsp;&nbsp;Net proceeds from short-term borrowings | $476945 | $182001 |
| &nbsp;&nbsp;Proceeds from revolving loan facilities | 81000 | 130000 |
| &nbsp;&nbsp;Repayment of revolving loan facilities | (81000) | (86000) |
| &nbsp;&nbsp;Debt issuance costs | (2825) | (2662) |
| &nbsp;&nbsp;Repayment of long-term borrowings |  | (9104) |
| &nbsp;&nbsp;Other, net | 361 | 64 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | $474481 | $214299 |
| Effect of exchange rate changes on cash | (997) | (761) |
| Increase (decrease) in cash, cash equivalents, and restricted cash | 15838 | (10690) |
| Cash and cash equivalents at beginning of period | 78254 | 92569 |
| Restricted cash at beginning of period | 7290 | 7224 |
| Cash, cash equivalents, and restricted cash at end of period | $101382 | $89103 |
| Other information: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes, net | $2609 | $2679 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest, net | 25988 | 30833 |
| Noncash investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncash amounts obtained as a beneficial interest in exchange for transferring trade receivables in a securitization transaction | 30017 | 60491 |
| *See "Notes to Condensed Consolidated Financial Statements"* |  |  |

---

------

---

| | | |
|:---|:---|:---|
| **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** |
| **Notes to Condensed Consolidated Financial Statements** | **Notes to Condensed Consolidated Financial Statements** | **Notes to Condensed Consolidated Financial Statements** |
| *(Unaudited)* | *(Unaudited)* | *(Unaudited)* |
| *(in thousands, except per share data)* | *(in thousands, except per share data)* | **<u>Page Number</u>** |
| <u>[Note 1](#i2474226e74764caf8765b48a7e12feb1_43)</u> | <u>[Basis of Presentation and Summary of Significant Accounting Policies](#i2474226e74764caf8765b48a7e12feb1_43)</u> | <u>[9](#i2474226e74764caf8765b48a7e12feb1_43)</u> |
| <u>[Note 2](#i2474226e74764caf8765b48a7e12feb1_46)</u> | <u>[New Accounting Standards](#i2474226e74764caf8765b48a7e12feb1_46)</u> | <u>[9](#i2474226e74764caf8765b48a7e12feb1_46)</u> |
| <u>[Note 3](#i2474226e74764caf8765b48a7e12feb1_49)</u> | <u>[Revenue Recognition](#i2474226e74764caf8765b48a7e12feb1_49)</u> | <u>[10](#i2474226e74764caf8765b48a7e12feb1_49)</u> |
| <u>[Note 4](#i2474226e74764caf8765b48a7e12feb1_52)</u> | <u>[Income Taxes](#i2474226e74764caf8765b48a7e12feb1_52)</u> | <u>[10](#i2474226e74764caf8765b48a7e12feb1_52)</u> |
| <u>[Note 5](#i2474226e74764caf8765b48a7e12feb1_55)</u> | <u>[(Loss) Earnings Per Share](#i2474226e74764caf8765b48a7e12feb1_55)</u> | <u>[11](#i2474226e74764caf8765b48a7e12feb1_55)</u> |
| <u>[Note 6](#i2474226e74764caf8765b48a7e12feb1_58)</u> | <u>[Restricted Cash](#i2474226e74764caf8765b48a7e12feb1_58)</u> | <u>[11](#i2474226e74764caf8765b48a7e12feb1_58)</u> |
| <u>[Note 7](#i2474226e74764caf8765b48a7e12feb1_61)</u> | <u>[Inventories, Net](#i2474226e74764caf8765b48a7e12feb1_61)</u> | <u>[11](#i2474226e74764caf8765b48a7e12feb1_61)</u> |
| <u>[Note 8](#i2474226e74764caf8765b48a7e12feb1_64)</u> | <u>[Equity Method Investments](#i2474226e74764caf8765b48a7e12feb1_64)</u> | <u>[12](#i2474226e74764caf8765b48a7e12feb1_64)</u> |
| <u>[Note 9](#i2474226e74764caf8765b48a7e12feb1_67)</u> | <u>[Variable Interest Entities](#i2474226e74764caf8765b48a7e12feb1_67)</u> | <u>[12](#i2474226e74764caf8765b48a7e12feb1_67)</u> |
| <u>[Note 10](#i2474226e74764caf8765b48a7e12feb1_70)</u> | <u>[Intangible Assets, Net](#i2474226e74764caf8765b48a7e12feb1_70)</u> | <u>[13](#i2474226e74764caf8765b48a7e12feb1_70)</u> |
| <u>[Note 11](#i2474226e74764caf8765b48a7e12feb1_73)</u> | <u>[Debt Arrangements](#i2474226e74764caf8765b48a7e12feb1_73)</u> | <u>[14](#i2474226e74764caf8765b48a7e12feb1_73)</u> |
| <u>[Note 12](#i2474226e74764caf8765b48a7e12feb1_76)</u> | <u>[Securitized Receivables](#i2474226e74764caf8765b48a7e12feb1_76)</u> | <u>[16](#i2474226e74764caf8765b48a7e12feb1_76)</u> |
| <u>[Note 13](#i2474226e74764caf8765b48a7e12feb1_79)</u> | <u>[Guarantees](#i2474226e74764caf8765b48a7e12feb1_79)</u> | <u>[17](#i2474226e74764caf8765b48a7e12feb1_79)</u> |
| <u>[Note 14](#i2474226e74764caf8765b48a7e12feb1_82)</u> | <u>[Derivative Financial Instruments](#i2474226e74764caf8765b48a7e12feb1_82)</u> | <u>[18](#i2474226e74764caf8765b48a7e12feb1_82)</u> |
| <u>[Note 15](#i2474226e74764caf8765b48a7e12feb1_85)</u> | <u>[Fair Value Measurements](#i2474226e74764caf8765b48a7e12feb1_85)</u> | <u>[18](#i2474226e74764caf8765b48a7e12feb1_85)</u> |
| <u>[Note 16](#i2474226e74764caf8765b48a7e12feb1_91)</u> | <u>[Contingencies and Other Information](#i2474226e74764caf8765b48a7e12feb1_91)</u> | <u>[19](#i2474226e74764caf8765b48a7e12feb1_91)</u> |
| <u>[Note 17](#i2474226e74764caf8765b48a7e12feb1_94)</u> | <u>[Equity-Based Compensation](#i2474226e74764caf8765b48a7e12feb1_94)</u> | <u>[19](#i2474226e74764caf8765b48a7e12feb1_94)</u> |
| <u>[Note 18](#i2474226e74764caf8765b48a7e12feb1_97)</u> | <u>[Related Party Transactions](#i2474226e74764caf8765b48a7e12feb1_97)</u> | <u>[20](#i2474226e74764caf8765b48a7e12feb1_97)</u> |
| <u>[Note 19](#i2474226e74764caf8765b48a7e12feb1_100)</u> | <u>[Segment Information](#i2474226e74764caf8765b48a7e12feb1_100)</u> | <u>[21](#i2474226e74764caf8765b48a7e12feb1_100)</u> |

---

------

**1. Basis of Presentation and Summary of Significant Accounting Policies**

The accompanying unaudited condensed consolidated interim financial statements represent the consolidation of Pyxus International, Inc. (the "Company", "Pyxus", "we", or "us") and all companies that Pyxus directly or indirectly controls, either through majority ownership or otherwise. These condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. In the opinion of management, the normal and recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows have been included.

These condensed consolidated interim financial statements should be read in conjunction with the Company's consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2025 filed on June 10, 2025. The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. Due to the seasonal nature of the Company's business, the results of operations for a fiscal quarter are not necessarily indicative of the operating results that may be attained for other quarters or a full fiscal year.

**2. New Accounting Standards**

***Recently Adopted Accounting Pronouncements***

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, *Segment Reporting: Improvements to Reportable Segment Disclosures*. This ASU amends FASB Topic 280 to permit the disclosure of multiple measures of a segment's profit or loss, and requires an entity with a single reportable segment to apply FASB Topic 280 in its entirety. In addition, this ASU requires the following new segment disclosures:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Significant segment expenses by reportable segment if regularly provided to the Chief Operating Decision Maker ("CODM") and included within the reported measure of segment profit or loss;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other segment items, which represents the difference between reported segment revenues less the significant segment expenses less reported segment profit or loss; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Title and position of the CODM.

Disclosures required under this new ASU and the existing segment profit or loss and assets disclosures currently required annually by FASB Topic 280 are to be disclosed in interim periods. The Company adopted the annual period disclosure requirements for its fiscal year ended March 31, 2025. The interim period disclosure requirements were adopted on April 1, 2025, and are included in "<u>[Note 19. Segment Information](#i2474226e74764caf8765b48a7e12feb1_100)</u>". The adoption of this new accounting standard resulted in additional disclosures for segment reporting, and did not have an impact on the Company's financial condition, results of operations, or cash flows.

***Accounting Pronouncements Not Yet Adopted***

In December 2023, the FASB issued ASU No. 2023-09, *Income Taxes: Improvements to Income Tax Disclosures*, to provide more disaggregation of income tax information mainly related to the effective tax rate reconciliation and the income taxes paid disclosure requirements. Under the new accounting rules, the tabular effective tax rate reconciliation must include specific categories with certain reconciling items based on the expected tax further disaggregated by nature and/or jurisdiction. Income taxes paid, net of refunds received, must be broken out by federal, state, and foreign taxes, and further disaggregated by individual jurisdictions based on total income taxes paid. These new annual disclosure requirements are effective for the Company's fiscal year ending March 31, 2026. Early adoption is permitted. This new standard will result in additional disclosures within the footnotes to the financial statements, and is not expected to have an impact on the Company's financial condition, results of operations, or cash flows.

In November 2024, the FASB issued ASU No. 2024-03, *Disaggregation of Income Statement Expenses*, which requires a tabular disclosure of relevant expense captions into prescribed natural expense categories. The annual disclosure requirements are effective for the Company's fiscal year ending March 31, 2028, and the interim period disclosure requirements are effective beginning April 1, 2028. Early adoption is permitted. This new standard will result in additional disclosures within the footnotes to the financial statements, and is not expected to have an impact on the Company's financial condition, results of operations, or cash flows.

------

**3. Revenue Recognition**

Product revenue is primarily processed tobacco sold to the customer. Processing and other revenues are mainly contracts to process customer-owned green tobacco. During such processing, ownership remains with the customers. All Other revenue is primarily composed of revenue from the sale of non-tobacco agriculture products. The following disaggregates sales and other operating revenues by major source, with the All Other category being included for purposes of reconciliation of the respective balances below of the Leaf segment (the Company's sole reportable segment) to the condensed consolidated financial statements:

---

| | | |
|:---|:---|:---|
| | Three Months Ended | Three Months Ended |
| | June 30, | June 30, |
| | 2025 | 2024 |
| Leaf: |  |  |
| &nbsp;&nbsp;Product revenue | $458238 | $589217 |
| &nbsp;&nbsp;Processing and other revenues | 50177 | 41746 |
| &nbsp;&nbsp;&nbsp;&nbsp;Leaf sales and other operating revenues | 508415 | 630963 |
| All Other: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;All Other sales and other operating revenues | 400 | 3892 |
| Total sales and other operating revenues | $508815 | $634855 |

---

The following summarizes activity in the allowance for expected credit losses:

---

| | | |
|:---|:---|:---|
| | Three Months Ended | Three Months Ended |
| | June 30, | June 30, |
| | 2025 | 2024 |
| Balance, beginning of period | $(24035) | $(23940) |
| &nbsp;&nbsp;Additions |  | (401) |
| &nbsp;&nbsp;Write-offs and other adjustments | (264) | 306 |
| Balance, end of period | (24299) | (24035) |
| Trade receivables | 230906 | 233088 |
| &nbsp;&nbsp;Trade receivables, net | $206607 | $209053 |

---

**4. Income Taxes**

The Company's quarterly provision for income taxes for the three months ended June 30, 2025 was calculated by applying the estimated annual effective tax rate to year-to-date pre-tax income or loss and adjusting for discrete items that occurred during the period. The Company's quarterly provision for income taxes for the three months ended June 30, 2024 was calculated using the discrete method, as allowed under FASB Accounting Standards Codification 740-270, *Income Taxes - Interim Reporting*. The discrete method used in the prior year calculates income tax expense as if the three-month interim period was an annual period.

The effective tax rate for the three months ended June 30, 2025 and 2024 was (59.6)% and 71.9%, respectively. For the three months ended June 30, 2025, the difference between the Company's effective rate and the U.S. statutory rate of 21.0% is primarily due to tax expense related to foreign currency gains, liabilities for unrecognized tax benefits, and nondeductible interest expense.

On July 4, 2025, the U.S. government enacted the One Big Beautiful Bill Act of 2025 ("OBBBA"). This legislation includes several changes to U.S. federal income tax law, including the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act and changes to the international tax framework. Certain provisions of the OBBBA are effective for the Company's fiscal year ending March 31, 2026, and the Company is currently evaluating the impact it will have on our condensed consolidated financial statements.

------

**5. (Loss) Earnings Per Share** 

The following summarizes the computation of (loss) earnings per share:

---

| | | |
|:---|:---|:---|
| | Three Months Ended | Three Months Ended |
| | June 30, | June 30, |
| | 2025 | 2024 |
| Net (loss) income attributable to Pyxus International, Inc. | $(15825) | $4642 |
| Basic weighted average shares outstanding | 25670 | 25461 |
| Plus: Dilutive equity awards<sup>(1)</sup> |  |  |
| &nbsp;&nbsp;Diluted weighted average shares outstanding | 25670 | 25461 |
| (Loss) earnings per share: |  |  |
| &nbsp;&nbsp;Basic | $(0.62) | $0.18 |
| &nbsp;&nbsp;Diluted | $(0.62) | $0.18 |
| <sup>(1)</sup> For the three months ended June 30, 2025 and 2024, 264 shares and 17 shares, respectively, related to outstanding restricted stock units have been excluded from the computation of diluted earnings per share because their effect would be antidilutive. | <sup>(1)</sup> For the three months ended June 30, 2025 and 2024, 264 shares and 17 shares, respectively, related to outstanding restricted stock units have been excluded from the computation of diluted earnings per share because their effect would be antidilutive. | <sup>(1)</sup> For the three months ended June 30, 2025 and 2024, 264 shares and 17 shares, respectively, related to outstanding restricted stock units have been excluded from the computation of diluted earnings per share because their effect would be antidilutive. |

---

**6. Restricted Cash**

The following summarizes the composition of restricted cash:

---

| | | | |
|:---|:---|:---|:---|
| | June 30, 2025 | June 30, 2024 | March 31, 2025 |
| Compensating balance for short-term borrowings | $542 | $542 | $542 |
| Escrow | 3588 | 3209 | 3534 |
| Grants | 357 | 1158 | 3116 |
| Other | 458 | 2152 | 98 |
| &nbsp;&nbsp;Total | $4945 | $7061 | $7290 |

---

**7. Inventories, Net**

The following summarizes the composition of inventories, net:

---

| | | | |
|:---|:---|:---|:---|
| | June 30, 2025 | June 30, 2024 | March 31, 2025 |
| Processed tobacco | $575922 | $605535 | $490410 |
| Unprocessed tobacco | 513882 | 375102 | 241832 |
| Other tobacco related | 26089 | 28083 | 25643 |
| All Other | 5895 | 5807 | 4066 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $1121788 | $1014527 | $761951 |

---

------

**8. Equity Method Investments**

The following summarizes the Company's equity method investments as of June 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Investee Name | Location | Primary Purpose | Ownership Percentage | Basis Difference<sup>(1)</sup> |
| Adams International Ltd. | Thailand | Purchase and process tobacco | 49% | $(4526) |
| Alliance One Industries India Private Ltd. | India | Purchase and process tobacco | 49% | (5770) |
| China Brasil Tabacos Exportadora S.A. | Brazil | Purchase and process tobacco | 49% | 43000 |
| Oryantal Tütün Paketleme Sanayi ve Ticaret A.Ş. | Turkey | Process tobacco | 50% | (416) |
| Purilum, LLC | U.S. | Produce flavor formulations and consumable e-liquids | 50% | 4589 |
| Siam Tobacco Export Corporation Ltd. | Thailand | Purchase and process tobacco | 49% | (6098) |
| <sup>(1)</sup> Basis differences for the Company's equity method investments are due to fair value adjustments recorded during fiscal 2021. | <sup>(1)</sup> Basis differences for the Company's equity method investments are due to fair value adjustments recorded during fiscal 2021. | <sup>(1)</sup> Basis differences for the Company's equity method investments are due to fair value adjustments recorded during fiscal 2021. | <sup>(1)</sup> Basis differences for the Company's equity method investments are due to fair value adjustments recorded during fiscal 2021. | <sup>(1)</sup> Basis differences for the Company's equity method investments are due to fair value adjustments recorded during fiscal 2021. |

---

The following summarizes financial information for these equity method investments:

---

| | | |
|:---|:---|:---|
| | Three Months Ended | Three Months Ended |
| | June 30, | June 30, |
| | 2025 | 2024 |
| Statement of operations: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales | $46504 | $56771 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 7052 | 7187 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income | (2666) | 5239 |

---

---

| | | | |
|:---|:---|:---|:---|
| | June 30, 2025 | June 30, 2024 | March 31, 2025 |
| Balance sheet: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current assets | $510324 | $533214 | $419192 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant, and equipment and other assets | 51932 | 57453 | 49243 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current liabilities | 425697 | 438293 | 328818 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term obligations and other liabilities | 4150 | 3468 | 4560 |

---

**9. Variable Interest Entities**

The Company holds variable interests in multiple entities that primarily procure or process inventory or are securitization entities. These variable interests relate to equity investments, receivables, guarantees, and securitized receivables. The following summarizes the Company's financial relationships with its unconsolidated variable interest entities:

---

| | | | |
|:---|:---|:---|:---|
| | June 30, 2025 | June 30, 2024 | March 31, 2025 |
| Investments in variable interest entities | $89200 | $96903 | $90239 |
| Receivables with variable interest entities | 1469 | 3980 |  |
| Guaranteed amounts to variable interest entities (not to exceed) | 15968 | 16392 | 15995 |

---

------

**10. Intangible Assets, Net**

The gross carrying amount and accumulated amortization of intangible assets consist of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2025 |
| | Weighted Average Remaining Useful Life | Gross Carrying Amount | Accumulated Amortization | Intangible Assets, Net |
| Intangibles subject to amortization: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer relationships | 7.2 years | $26101 | $(10513) | $15588 |
| &nbsp;&nbsp;&nbsp;&nbsp;Technology | 3.1 years | 11618 | (7218) | 4400 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade names | 9.2 years | 11300 | (3901) | 7399 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total |  | $49019 | $(21632) | $27387 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | June 30, 2024 | June 30, 2024 | June 30, 2024 | June 30, 2024 |
| | Weighted Average Remaining Useful Life | Gross Carrying Amount | Accumulated Amortization | Intangible Assets, Net |
| Intangibles subject to amortization: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer relationships | 8.2 years | $26101 | $(8338) | $17763 |
| &nbsp;&nbsp;&nbsp;&nbsp;Technology | 4.2 years | 12948 | (6189) | 6759 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade names | 10.2 years | 11300 | (3094) | 8206 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total |  | $50349 | $(17621) | $32728 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | March 31, 2025 | March 31, 2025 | March 31, 2025 | March 31, 2025 |
| | Weighted Average Remaining Useful Life | Gross Carrying Amount | Accumulated Amortization | Intangible Assets, Net |
| Intangibles subject to amortization: |  |  |  |  |
| &nbsp;&nbsp;Customer relationships | 7.4 years | $26101 | $(9969) | $16132 |
| &nbsp;&nbsp;Technology | 3.4 years | 11618 | (6844) | 4774 |
| &nbsp;&nbsp;Trade names | 9.4 years | 11300 | (3699) | 7601 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total |  | $49019 | $(20512) | $28507 |

---

The following summarizes amortization expense for definite-lived intangible assets:

---

| | | |
|:---|:---|:---|
| | Three Months Ended | Three Months Ended |
| | June 30, | June 30, |
| | 2025 | 2024 |
| Amortization expense | $1120 | $1151 |

---

------

**11. Debt Arrangements**

The following summarizes debt and notes payable:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | Interest Rate | Interest Rate | June 30, 2025 | June 30, 2024 | March 31, 2025 |
| Senior secured credit facilities: |  |  |  |  |  |
| &nbsp;&nbsp;ABL Credit Facility | 7.8% | <sup>(1)</sup> | $— | $44000 | $— |
| Senior secured notes: |  |  |  |  |  |
| &nbsp;&nbsp;10.0% Notes Due 2024 | 10.0% | <sup>(1)</sup> |  | 20328 |  |
| &nbsp;&nbsp;8.5% Notes Due 2027<sup>(2)</sup> | 8.5% | <sup>(1)</sup> | 146046 | 178423 | 145820 |
| Senior secured term loans: |  |  |  |  |  |
| &nbsp;&nbsp;Intabex Term Loans<sup>(3)</sup> | 13.0% | <sup>(1)</sup> | 187288 | 186770 | 187144 |
| &nbsp;&nbsp;Pyxus Term Loans<sup>(4)</sup> | 13.0% | <sup>(1)</sup> | 121757 | 122268 | 121886 |
| Other Debt: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term debt | 8.8% | <sup>(1)</sup> |  | 117 | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;Notes payable<sup>(5)</sup> | 9.0% | <sup>(1)</sup> | 880925 | 679399 | 395030 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total debt |  |  | $1336016 | $1231305 | $849892 |
| Short-term<sup>(5)</sup> |  |  | $880925 | $679399 | $395030 |
| Long-term: |  |  |  |  |  |
| &nbsp;&nbsp;Current portion of long-term debt |  |  | $— | $20445 | $12 |
| &nbsp;&nbsp;Long-term debt |  |  | 455091 | 531461 | 454850 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total |  |  | $455091 | $551906 | $454862 |
| Letters of credit |  |  | $8939 | $7669 | $7790 |
| <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended June 30, 2025 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended June 30, 2025 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended June 30, 2025 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended June 30, 2025 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended June 30, 2025 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended June 30, 2025 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. |
| <sup>(2)</sup> Balance of $146,046 is net of a debt discount of $2,293. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,046 is net of a debt discount of $2,293. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,046 is net of a debt discount of $2,293. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,046 is net of a debt discount of $2,293. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,046 is net of a debt discount of $2,293. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,046 is net of a debt discount of $2,293. Total repayment at maturity is $148,339. |
| <sup>(3)</sup> Balance of $187,288 is net of a debt discount of $1,745. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,288 is net of a debt discount of $1,745. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,288 is net of a debt discount of $1,745. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,288 is net of a debt discount of $1,745. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,288 is net of a debt discount of $1,745. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,288 is net of a debt discount of $1,745. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. |
| <sup>(4)</sup> Balance of $121,757 is net of a debt premium of $1,552. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,757 is net of a debt premium of $1,552. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,757 is net of a debt premium of $1,552. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,757 is net of a debt premium of $1,552. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,757 is net of a debt premium of $1,552. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,757 is net of a debt premium of $1,552. Total repayment at maturity is $120,205. |
| <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. |

---

***Outstanding Senior Secured Debt***

*ABL Credit Facility*

On February 8, 2022, the Company's wholly owned subsidiary, Pyxus Holdings, Inc. ("Pyxus Holdings"), certain subsidiaries of Pyxus Holdings (together with Pyxus Holdings, the "Borrowers"), and the Company and its wholly owned subsidiary, Pyxus Parent, Inc. ("Pyxus Parent"), as parent guarantors, entered into an ABL Credit Agreement (as amended, the "ABL Credit Agreement"), dated as of February 8, 2022, by and among Pyxus Holdings, as Borrower Agent, the Borrowers and parent guarantors party thereto, the lenders party thereto, and PNC Bank, National Association, as Administrative Agent and Collateral Agent, to establish an asset-based revolving credit facility (the "ABL Credit Facility"), the proceeds of which may be used to refinance existing senior bank debt, pay fees and expenses related to the ABL Credit Facility, partially fund capital expenditures, and provide for the ongoing working capital needs of the Borrowers. The ABL Credit Agreement was amended on May 12, 2025 to, among other things increase the aggregate amount of the revolving loan commitments under the ABL Credit Facility to $150,000, and to extend the maturity to May 12, 2030 or, if earlier, 90 days prior to the earliest stated maturity date of the outstanding senior secured notes and the senior secured term loans (each currently scheduled to mature on December 31, 2027). A detailed description of the ABL Credit Agreement is included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2025.

At June 30, 2025, the Borrowers and the parent guarantors under the ABL Credit Agreement were in compliance with the covenants under the ABL Credit Agreement.

------

*Intabex Term Loans*

On February 6, 2023, Pyxus Holdings entered into the Intabex Term Loan Credit Agreement, dated as of February 6, 2023 (the "Intabex Term Loan Credit Agreement"), by and among, Pyxus Holdings, the guarantors party thereto, the lenders party thereto and Alter Domus (US) LLC ("Alter Domus"), as administrative agent and senior collateral agent. The Intabex Term Loan Credit Agreement established a term loan credit facility in an aggregate principal amount of approximately $189,033 (the "Intabex Credit Facility"), under which term loans in the full aggregate principal amount of the Intabex Credit Facility (the "Intabex Term Loans") were deemed made in exchange for certain outstanding term debt of Pyxus Holdings, accrued and unpaid PIK interest thereon, and related fees. The Intabex Term Loans bear interest, at Pyxus Holdings' option, at either (i) a term SOFR rate (subject to a floor of 1.5%) plus 8.0% per annum or (ii) an alternate base rate plus 7.0% per annum. The Intabex Term Loans are stated to mature on December 31, 2027. A detailed description of the Intabex Term Loan Credit Agreement is included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2025. At June 30, 2025, Pyxus Holdings and the guarantors under the Intabex Term Loan Credit Agreement were in compliance with all covenants under the Intabex Term Loan Credit Agreement.

*Pyxus Term Loans*

On February 6, 2023, Pyxus Holdings entered into the Pyxus Term Loan Credit Agreement, dated as of February 6, 2023 (the "Pyxus Term Loan Credit Agreement"), by and among, Pyxus Holdings, the guarantors party thereto, the lenders party thereto and Alter Domus, as administrative agent and senior collateral agent, to establish a term loan credit facility in an aggregate principal amount of approximately $130,550 (the "Pyxus Credit Facility"), under which term loans in the full aggregate principal amount of the Pyxus Credit Facility (the "Pyxus Term Loans") were deemed made in exchange for certain outstanding term debt of Pyxus Holdings and applicable accrued and unpaid PIK interest thereon. The Pyxus Term Loans bear interest, at Pyxus Holdings' option, at either (i) a term SOFR rate (subject to a floor of 1.5%) plus 8.0% per annum or (ii) an alternate base rate plus 7.0% per annum. The Pyxus Term Loans are stated to mature on December 31, 2027. A detailed description of the Pyxus Term Loan Credit Agreement is included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2025. At June 30, 2025, Pyxus Holdings and the guarantors under the Pyxus Term Loan Credit Agreement were in compliance with all covenants under the Pyxus Term Loan Credit Agreement.

*8.50% Senior Secured Notes due 2027*

Pursuant to an exchange offer made by Pyxus Holdings and accepted by holders of approximately 92.7% of the aggregate principal amount of the outstanding 10.0% Senior Secured First Lien Notes due 2024 issued by Pyxus Holdings (the "2024 Notes") pursuant to that certain Indenture, dated as of August 24, 2020 (the "2024 Notes Indenture"), by and among Pyxus Holdings, the guarantors party thereto and the trustee, collateral agent, registrar and paying agent thereunder, on February 6, 2023, Pyxus Holdings issued approximately $260,452 in aggregate principal amount of 8.5% Senior Secured Notes due December 31, 2027 (the "2027 Notes") to the exchanging holders of the 2024 Notes for an equal principal amount of 2024 Notes. The 2027 Notes were issued pursuant to the Indenture, dated as of February 6, 2023 (the "2027 Notes Indenture"), among Pyxus Holdings, the guarantors party thereto, and Wilmington Trust, National Association, as trustee, and Alter Domus, as collateral agent. The 2027 Notes bear interest at a rate of 8.5% per annum, which interest is computed on the basis of a 360-day year comprised of twelve 30-day months. The 2027 Notes are stated to mature on December 31, 2027. A detailed description of the 2027 Notes and the 2027 Notes Indenture is included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2025. At June 30, 2025, Pyxus Holdings and the guarantors of the 2027 Notes were in compliance with all covenants under the 2027 Notes Indenture.

***Related Party Transactions***

Based on a Schedule 13D/A filed with the SEC on March 25, 2024, by Monarch Alternative Capital LP (the "Monarch Investor"), MDRA GP LP and Monarch GP LLC, the Monarch Investor reported beneficial ownership of 6,125 shares of the Company's common stock, representing approximately 24.9% of the outstanding shares of the Company's common stock. An individual designated by the Monarch Investor serves as a director of Pyxus.

On March 21, 2024, Pyxus Holdings entered into an agreement (the "Debt Repurchase Agreement") with funds affiliated with the Monarch Investor to purchase $77,922 of aggregate principal amount of their holdings in the 2027 Notes for $60,000, a 23.0% discount to par value, plus accrued and unpaid interest and specified customary fees. The purchase of $77,922 aggregate principal amount of the 2027 Notes for a total of $62,339 (including fees and accrued and unpaid interest) was completed on March 28, 2024.

The Debt Repurchase Agreement also included the right of Pyxus Holdings, at its option, to purchase from such holders an additional $34,191 aggregate principal amount of the 2027 Notes for $26,327, a 23.0% discount to par value, plus accrued and unpaid interest, and $10,345 aggregate principal amount of the Pyxus Term Loans for $9,104, a 12.0% discount to par value, plus accrued and unpaid interest. On April 12, 2024, Pyxus Holdings exercised its rights to complete these repurchases by September 30, 2024.

------

On May 31, 2024, Pyxus Holdings completed the purchase of $10,345 of aggregate principal amount of the Pyxus Term Loans for a total of $9,435 (including accrued and unpaid interest).

On August 2, 2024, Pyxus Holdings completed the purchase of $34,191 of aggregate principal amount of the 2027 Notes for a total of $26,707 (including accrued and unpaid interest).

The Debt Repurchase Agreement and the transactions contemplated thereunder were approved and determined to be on terms and conditions at least as favorable to the Company and its subsidiaries as could reasonably have been obtained in a comparable arm's-length transaction with an unaffiliated party by a majority of the disinterested members of the Board of Directors of Pyxus. Refer to "<u>[Note 18. Related Party Transactions](#i2474226e74764caf8765b48a7e12feb1_97)</u>" for additional information.

***Other Outstanding Debt***

*2024 Notes*

The 2024 Notes bore interest at a rate of 10.0% per year, payable semi-annually in arrears in cash on February 15 and August 15 of each year. On August 26, 2024, upon maturity of the 2024 Notes, Pyxus Holdings paid $20,442, which included $51 for accrued and unpaid interest, to retire the 2024 Notes.

*Foreign Seasonal Lines of Credit*

Excluding long-term credit agreements, the Company typically finances its non-U.S. operations with committed and uncommitted short-term seasonal lines of credit arrangements with a number of banks. These operating lines are generally seasonal in nature, typically extending for a term of 180 days to 365 days corresponding to the tobacco crop cycle in that location. For uncommitted facilities, the lenders have the right to cease making loans and demand repayment of loans at any time or at specified dates. These loans are generally renewed at the outset of each tobacco season. Certain of the seasonal lines of credit are secured by trade receivables and inventories as collateral and are guaranteed by the Company and certain of its subsidiaries. As of June 30, 2025, the total borrowing capacity under individual foreign seasonal lines of credit range up to $144,010. As of June 30, 2025, the aggregate amount available for borrowing under the seasonal lines of credit was $171,220. At June 30, 2025, the Company was permitted to borrow under foreign seasonal lines of credit up to a total $1,025,240, subject to limitations under the ABL Credit Agreement and the agreements governing the Intabex Term Loans, the Pyxus Term Loans, and the 2027 Notes. At June 30, 2025, the Company, and its subsidiaries, were in compliance with the covenants associated with its short-term seasonal lines of credit.

**12. Securitized Receivables**

The Company sells trade receivables to unaffiliated financial institutions under various accounts receivable securitization facilities, two of which are subject to annual renewal.

Under the first facility, with Finacity Corporation (the "Finacity Facility"), the Company continuously sells a designated pool of trade receivables to a special purpose entity, which sells 100% of the receivables to an unaffiliated financial institution. Following the sale and transfer of the receivables to the special purpose entity, the receivables are isolated from the Company and its affiliates, and effective control of the receivables is passed to the unaffiliated financial institution, which has all rights, including the right to pledge or sell the receivables. This facility requires a minimum level of deferred purchase price be retained by the Company in connection with the sales of the receivables to the unaffiliated financial institution. The Company continues to service, administer, and collect the receivables on behalf of the special purpose entity and receives a servicing fee of 0.5% of serviced receivables per annum. As the Company estimates the expected fee it receives in return for its obligation to service these receivables is at fair value, no servicing assets or liabilities are recognized. Servicing fees are recorded as a reduction of selling, general, and administrative expenses within the condensed consolidated statements of operations. As of June 30, 2025, the investment limit of this facility was $120,000 of trade receivables.

Under the second facility, the Company offers trade receivables for sale to an unaffiliated financial institution, which are then subject to acceptance by the unaffiliated financial institution. Following the sale and transfer of the receivables to the unaffiliated financial institution, the receivables are isolated from the Company and its affiliates, and effective control of the receivables is passed to the unaffiliated financial institution, which has all rights, including the right to pledge or sell the receivables. Although the Company continues to service, administer, and collect the receivables on behalf of the unaffiliated financial institution, the Company does not receive a servicing fee, and as a result, has established a servicing liability based upon unobservable inputs, primarily discounted cash flow. As of June 30, 2025, the investment limit under the second facility was $160,000 of trade receivables.

As servicer for the Finacity Facility and the second facility, the Company may receive funds that are due to the unaffiliated financial institutions which are net settled on the next settlement date. As of June 30, 2025 and 2024, and March 31, 2025, trade

------

receivables, net in the condensed consolidated balance sheets has been reduced by $1,056, $8,219, and $2,190 as a result of the net settlement, respectively. Refer to "<u>[Note 15. Fair Value Measurements](#i2474226e74764caf8765b48a7e12feb1_85)</u>" for additional information.

Under the other facilities, the Company offers trade receivables for sale to unaffiliated financial institutions, which are then subject to acceptance by the unaffiliated financial institutions. Following the sale and transfer of the receivables to the unaffiliated financial institution, the receivables are isolated from the Company and its affiliates, and effective control of the receivables is passed to the unaffiliated financial institution, which has all rights, including the right to pledge or sell the receivables. As of June 30, 2025, the investment limits under these other facilities were variable based on qualifying sales.

The following summarizes the Company's accounts receivable outstanding in the securitization facilities, which represents trade receivables sold into the program that have not been collected from the customer, and related beneficial interests, which represents the Company's residual interest in receivables sold that have not been collected from the customer:

---

| | | | |
|:---|:---|:---|:---|
| | June 30, 2025 | June 30, 2024 | March 31, 2025 |
| Receivables outstanding in facility | $167433 | $260973 | $355246 |
| Beneficial interests | 16103 | 25640 | 29354 |

---

Cash proceeds from the sale of trade receivables is comprised of a combination of cash and a deferred purchase price receivable. Deferred purchase price receivable is realized after the collection of the underlying trade receivables sold by the purchasers. The following summarizes the Company's cash purchase price and deferred purchase price:

---

| | | |
|:---|:---|:---|
| | Three Months Ended | Three Months Ended |
| | June 30, | June 30, |
| | 2025 | 2024 |
| Cash proceeds: |  |  |
| &nbsp;&nbsp;Cash purchase price | $115034 | $243109 |
| &nbsp;&nbsp;Deferred purchase price | 41007 | 31741 |

---

**13. Guarantees** 

In certain markets, the Company guarantees bank loans for suppliers to finance their crops. The Company also guarantees bank loans of certain unconsolidated subsidiaries. The following summarizes amounts guaranteed and the fair value of those guarantees:

---

| | | | |
|:---|:---|:---|:---|
| | June 30, 2025 | June 30, 2024 | March 31, 2025 |
| Amounts guaranteed (not to exceed) | $83519 | $79192 | $110660 |
| Amounts outstanding under guarantee<sup>(1)</sup> | 47948 | 41581 | 80045 |
| Fair value of guarantees | 3287 | 2611 | 6459 |
| Amounts due to local banks on behalf of suppliers for government subsidized rural credit financing | 7478 | 526 | 13787 |
| <sup>(1)</sup> Most of the guarantees outstanding at June 30, 2025 expire within one year. | <sup>(1)</sup> Most of the guarantees outstanding at June 30, 2025 expire within one year. | <sup>(1)</sup> Most of the guarantees outstanding at June 30, 2025 expire within one year. | <sup>(1)</sup> Most of the guarantees outstanding at June 30, 2025 expire within one year. |

---

------

**14. Derivative Financial Instruments**

The Company uses forward or option currency contracts to manage risks associated with foreign currency exchange rates on foreign operations. These contracts are for green tobacco purchases, processing costs, and selling, general, and administrative expenses. The Company recorded a net gain of $1,868 and $851 from its derivative financial instruments in cost of goods and services sold for the three months ended June 30, 2025 and 2024, respectively.

As of June 30, 2025 and 2024, and March 31, 2025, the Company recorded current derivative assets of $1,322, $0, and $982 included within other current assets, and current derivative liabilities of $0, $1,834, and $57, included within accrued expenses and other current liabilities, respectively. Refer to "<u>[Note 15. Fair Value Measurements](#i2474226e74764caf8765b48a7e12feb1_85)</u>" for additional information.

The following summarizes the U.S. Dollar notional amount of derivative contracts outstanding:

---

| | | | |
|:---|:---|:---|:---|
| | June 30, 2025 | June 30, 2024 | March 31, 2025 |
| U.S. Dollar notional outstanding | $14250 | $23300 | $49500 |

---

**15. Fair Value Measurements**

The following summarizes the financial assets and liabilities measured at fair value on a recurring basis:&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2024 | June 30, 2024 | June 30, 2024 | March 31, 2025 | March 31, 2025 | March 31, 2025 |
| | Level 2 | Level 3 | Total<br>at Fair <br>Value | Level 2 | Level 3 | Total<br>at Fair <br>Value | Level 2 | Level 3 | Total<br>at Fair <br>Value |
| Financial Assets: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivative financial instruments | $1322 | $— | $1322 | $— | $— | $— | $982 | $— | $982 |
| &nbsp;&nbsp;&nbsp;&nbsp;Securitized beneficial interests |  | 16103 | 16103 |  | 25640 | 25640 |  | 29354 | 29354 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1322 | $16103 | $17425 | $— | $25640 | $25640 | $982 | $29354 | $30336 |
| Financial Liabilities: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivative financial instruments | $— | $— | $— | $1834 | $— | $1834 | $57 | $— | $57 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt<sup>(1)</sup> | 439316 |  | 439316 | 455789 | 160 | 455949 | 433885 | 12 | 433897 |
| &nbsp;&nbsp;&nbsp;&nbsp;Guarantees |  | 3287 | 3287 |  | 2611 | 2611 |  | 6459 | 6459 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $439316 | $3287 | $442603 | $457623 | $2771 | $460394 | $433942 | $6471 | $440413 |
| <sup>(1)</sup> This fair value measurement disclosure does not affect the condensed consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the condensed consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the condensed consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the condensed consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the condensed consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the condensed consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the condensed consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the condensed consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the condensed consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the condensed consolidated balance sheets. |

---

The following summarizes the reconciliation of changes in Level 3 instruments measured on a recurring basis:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended | Three Months Ended | Three Months Ended | Three Months Ended | Three Months Ended | Three Months Ended |
| | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2024 | June 30, 2024 | June 30, 2024 |
| | Securitized Beneficial Interests | Long-Term Debt | Guarantees | Securitized Beneficial Interests | Long-Term Debt | Guarantees |
| Balance, beginning of period | $29354 | $12 | $6459 | $15036 | $160 | $5097 |
| &nbsp;&nbsp;Issuances | 30431 |  | 300 | 61029 |  | 938 |
| &nbsp;&nbsp;Settlements | (42023) | (12) | (1242) | (45233) |  | (715) |
| &nbsp;&nbsp;Losses recognized in earnings | (1659) |  | (2230) | (5192) |  | (2709) |
| Balance, end of period | $16103 | $— | $3287 | $25640 | $160 | $2611 |

---

For the three months ended June 30, 2025 and 2024, the impact to earnings attributable to the change in unrealized losses on securitized beneficial interests was $633 and $1,250, respectively. Gains and losses included in earnings are reported in other expense, net.

------

**16. Contingencies and Other Information**

***Brazilian Tax Credits***

The government in the Brazilian State of Parana ("Parana") issued a tax assessment on October 26, 2007 with respect to local intrastate trade tax credits that result primarily from tobacco transferred between states within Brazil. At June 30, 2025, the assessment for intrastate trade tax credits taken is $2,419 and the total assessment including penalties and interest is $10,408. The Company believes it has properly complied with Brazilian law and will contest any assessment through the judicial process. Should the Company lose in the judicial process, the loss of the intrastate trade tax credits would have a material impact on the financial statements of the Company.

***Other Matters***

In addition to the above-mentioned matters, the Company or certain of its subsidiaries are involved in other litigation or legal matters incidental to their business activities, including tax matters. While the outcome of these matters cannot be predicted with certainty, they are being vigorously defended and the Company does not currently expect that any of them will have a material adverse effect on its business or financial position. However, should one or more of these matters be resolved in a manner adverse to its current expectation, the effect on the Company's results of operations for a particular fiscal reporting period could be material.

**17. Equity-Based Compensation**

Pursuant to the Pyxus International, Inc. Amended and Restated 2020 Incentive Plan (the "Incentive Plan"), a total of 3,612 shares (which amounts are presented in thousands) have been authorized for grants of equity-based awards to certain employees and non-employee directors. During the three months ended June 30, 2025 and 2024, the Company recognized total equity-based compensation expense of $237 and $3,031, respectively, which is recorded in selling, general, and administrative expenses within the condensed consolidated statements of operations. The amount recorded during the three months ended June 30, 2024 included the impact of a cumulative catch-up adjustment due to the modification on May 10, 2024 of awards then outstanding under the Incentive Plan.

***Restricted Stock Units***

Restricted stock units granted under the Incentive Plan are earned ratably for certain employees, subject to their continued employment, from the date of the award to March 31, 2027, and for certain non-employee directors, subject to continued board service, from the date of the award to August 14, 2025. Restricted stock units vest upon the earlier of March 31, 2031 or the occurrence of a change-in-control event or a liquidity event as such terms are defined under the restricted stock unit award agreement. The following summarizes activity for restricted stock units:

---

| | | |
|:---|:---|:---|
| *(in thousands except grant date fair value)* | Restricted Stock Units | Weighted Average Grant Date Fair Value Per Share |
| Nonvested, March 31, 2025 | 1724 | $3.46 |
| &nbsp;&nbsp;Canceled or forfeited | (23) | 3.50 |
| Nonvested, June 30, 2025 | 1701 | $3.46 |

---

Unrecognized compensation cost for restricted stock units is $1,532 as of June 30, 2025, and is expected to be recognized over a weighted average period of 1.75 years, representing the weighted average remaining service period related to the awards, subject to adjustments for actual forfeitures.

***Performance-Based Stock Units***

Under the terms of the performance-based stock units, the amount of shares to be issued to certain employees (ranging from 0% to 200% of the number of shares to be issued at the target performance level) will be contingent upon the per share price achieved in a liquidity event (as defined under the terms of the performance-based stock unit award agreement), subject to continued employment through the date of a liquidity event. The contingent liquidity event is not probable as of June 30, 2025, and accordingly, no equity-based compensation expense has been recognized for performance-based stock units. The following summarizes activity for performance-based stock units (at the target performance level):

---

| | | |
|:---|:---|:---|
| *(in thousands except grant date fair value)* | Performance-Based Stock Units | Weighted Average Grant Date Fair Value Per Share |
| Nonvested, March 31, 2025 | 553 | $4.36 |
| &nbsp;&nbsp;Canceled or forfeited | (26) | 4.36 |
| Nonvested, June 30, 2025 | 527 | $4.36 |

---

------

**18. Related Party Transactions**

The Company engages in transactions with its equity method investees primarily for the procuring and processing of inventory. The following summarizes activities with the Company's equity method investees:

---

| | | |
|:---|:---|:---|
| | Three Months Ended | Three Months Ended |
| | June 30, | June 30, |
| | 2025 | 2024 |
| &nbsp;&nbsp;Sales | $9055 | $10575 |
| &nbsp;&nbsp;Purchases | 27309 | 34886 |

---

The Company included the following related party balances in its condensed consolidated balance sheets:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | June 30, 2025 | June 30, 2024 | March 31, 2025 | Location in Condensed Consolidated Balance Sheet |
| Accounts receivable, related parties | $1519 | $4080 | $50 | &nbsp;&nbsp;Other receivables |
| Accounts payable, related parties | 18286 | 12041 | 19731 | &nbsp;&nbsp;Accounts payable |
| Advances from related parties | 5909 | 1247 |  | &nbsp;&nbsp;Advances from customers |

---

*Transactions with Significant Shareholders*

Based on a Schedule 13D/A filed with the SEC on June 13, 2024 by Glendon Capital Management, L.P. (the "Glendon Investor"), Holly Kim Olsen, Glendon Opportunities Fund, L.P. and Glendon Opportunities Fund II, L.P., the Glendon Investor reported beneficial ownership of 8,315 shares of the Company's common stock, representing approximately 33.8% of the outstanding shares of the Company's common stock. A representative of the Glendon Investor serves as a director of Pyxus. Based on a Schedule 13G/A filed with the SEC on September 3, 2024 by Owl Creek Asset Management, L.P. and Jeffrey A. Altman, Owl Creek Asset Management, L.P. is the investment manager of certain funds and reported beneficial ownership of 3,865 shares of the Company's common stock on August 31, 2024, representing approximately 15.7% of the outstanding shares of the Company's common stock. Funds managed by the Glendon Investor, funds managed by the Monarch Investor, and funds managed by Owl Creek Asset Management, L.P., (such funds are collectively referred to as the "Investor-Affiliated Funds") were holders, in part, of the Intabex Term Loans, the Pyxus Term Loans and the 2027 Notes, which are described in "<u>[Note 11. Debt Arrangements](#i2474226e74764caf8765b48a7e12feb1_73)</u>," during the three months ended June 30, 2025.

On August 21, 2024, the Company entered into a privately negotiated transaction with CI Investments, Inc. ("CI Investments"), which at that time was a beneficial owner of greater than five percent of the Company's common stock outstanding, to repurchase 392 (which amount is presented in thousands) shares of its common stock for approximately $1,000, inclusive of broker commission fees, which transaction was completed on August 22, 2024. This transaction was approved, and determined to be on terms and conditions at least as favorable to the Company and its subsidiaries as could reasonably have been obtained in a comparable arm's-length transaction with an unaffiliated party, by a majority of the disinterested members of the Board of Directors of Pyxus. Following the completion of this transaction and other contemporaneous dispositions of the Company's common stock by CI Investments, CI Investments ceased to be a beneficial owner of more than five percent of the Company's common stock outstanding.

Accrued expenses and other current liabilities as presented in the condensed consolidated balance sheets as of June 30, 2025 and 2024, and March 31, 2025, includes $1,499, $1,894, and $1,600, respectively, of interest payable to Investor-Affiliated Funds and CI Investments (applicable only for the periods in which CI Investments was a beneficial owner of more than five percent of the Company's common stock outstanding). Interest expense as presented in the condensed consolidated statements of operations includes $5,466 and $7,261 for the three months ended June 30, 2025 and 2024, respectively, that relates to the Investor-Affiliated Funds and CI Investments (applicable only for the periods in which CI Investments was a beneficial owner of more than five percent of the Company's common stock outstanding).

The holders of senior debt that are parties to the Debt Repurchase Agreement entered into on March 21, 2024 are funds affiliated with the Monarch Investor and of which the Monarch Investor is the investment advisor. The Debt Repurchase Agreement and the transactions contemplated thereby, including the exercise by Pyxus Holdings of its right to purchase the Pyxus Term Loans and additional 2027 Notes thereunder on April 12, 2024, were approved, and determined to be on terms and conditions at least as favorable to the Company and its subsidiaries as could reasonably have been obtained in a comparable arm's length transaction with an unaffiliated party, by a majority of the disinterested members of the Board of Directors of Pyxus. Under the terms of the Debt Repurchase Agreement, the Company has paid the following amounts to funds affiliated with the Monarch Investor:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On March 28, 2024, the Company paid a total of $62,339, which included $1,849 of accrued and unpaid interest and $490 in other fees, to retire $77,922 of aggregate principal amount of the 2027 Notes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On May 31, 2024, the Company paid a total of $9,435, which included $332 of accrued and unpaid interest, to retire $10,345 of aggregate principal amount of the Pyxus Term Loans.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On August 2, 2024, the Company paid a total of $26,707, which included $379 of accrued and unpaid interest, to retire $34,191 of aggregate principal amount of the 2027 Notes.

Upon completion of the transactions under the Debt Repurchase Agreement, the Monarch Investor is no longer a holder of the 2027 Notes and the Pyxus Term Loans. The Monarch Investor remains a related party as a holder of the Intabex Term Loan and a beneficial owner of more than five percent of the outstanding shares of common stock of the Company.

**19. Segment Information** 

The following summarizes segment information, with the All Other category being included for purposes of reconciliation of the respective balances of the Leaf segment (the Company's sole reportable segment) to the condensed consolidated financial statements:

---

| | | |
|:---|:---|:---|
| | Three Months Ended | Three Months Ended |
| | June 30, | June 30, |
| | 2025 | 2024 |
| Sales and other operating revenues: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Leaf | $508415 | $630963 |
| &nbsp;&nbsp;&nbsp;&nbsp;All Other | 400 | 3892 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated sales and other operating revenues | $508815 | $634855 |
| Cost of goods and services sold: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Leaf | $443386 | $546188 |
| &nbsp;&nbsp;&nbsp;&nbsp;All Other | (197) | 4815 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated cost of goods and services sold | $443189 | $551003 |
| Selling, general, and administrative expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Leaf | $38735 | $38792 |
| &nbsp;&nbsp;&nbsp;&nbsp;All Other | 1634 | 1870 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated selling, general, and administrative expenses | $40369 | $40662 |
| Other segment items:<sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Leaf | $4205 | $3502 |
| &nbsp;&nbsp;&nbsp;&nbsp;All Other | (29) | (872) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated other segment items | $4176 | $2630 |
| &nbsp;&nbsp;&nbsp;&nbsp;Leaf segment operating income | $22089 | $42482 |
| &nbsp;&nbsp;&nbsp;&nbsp;All Other operating loss | (1008) | (1922) |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset impairment charges | 81 | 103 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated operating income | $21000 | $40457 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on debt retirement |  | 1323 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 29767 | 33272 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loss) income before income taxes and other items | $(8767) | $8508 |
| <sup>(1)</sup> Represents the other expense, net caption within the condensed consolidated statements of operations.  | <sup>(1)</sup> Represents the other expense, net caption within the condensed consolidated statements of operations.  | <sup>(1)</sup> Represents the other expense, net caption within the condensed consolidated statements of operations.  |

---

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Three months ended | Three months ended | Three months ended | Three months ended | Three months ended | Three months ended |
| | June 30, | June 30, | June 30, | June 30, | June 30, | June 30, |
| | 2025 | 2025 | 2025 | 2024 | 2024 | 2024 |
| | Leaf | All Other | Total | Leaf | All Other | Total |
| Depreciation and amortization | $4800 | $369 | $5169 | $4723 | $404 | $5127 |
| Capital expenditures | 2008 | 656 | 2664 | 4093 | 255 | 4348 |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | June 30, 2025 | June 30, 2025 | June 30, 2025 | June 30, 2024 | June 30, 2024 | June 30, 2024 | March 31, 2025 | March 31, 2025 | March 31, 2025 |
| | Leaf | All Other | Total | Leaf | All Other | Total | Leaf | All Other | Total |
| Assets | $1904739 | $35786 | $1940525 | $1752886 | $39825 | $1792711 | $1466400 | $37443 | $1503843 |
| Trade and other receivables, net | 222909 | 381 | 223290 | 225532 | 563 | 226095 | 204054 | 175 | 204229 |
| Equity in net assets of investee companies | 89198 | 6461 | 95659 | 96912 | 6906 | 103818 | 90238 | 6690 | 96928 |

---

------

**<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>**

***Forward-Looking Statements***

Readers are cautioned that the statements contained in this report regarding expectations of our performance or other matters that may affect our business, results of operations, or financial condition are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements, which are based on current expectations of future events, may be identified by the use of words such as "guidance", "strategy," "expects," "continues," "plans," "anticipates," "believes," "will," "estimates," "intends," "projects," "goals," "targets," and other words of similar meaning. These statements also may be identified by the fact that they do not relate strictly to historical or current facts. If underlying assumptions prove inaccurate, or if known or unknown risks or uncertainties materialize, actual results could vary materially from those anticipated, estimated, or projected. These risks and uncertainties include those discussed in this Quarterly Report on Form 10-Q, in our Annual Report on Form 10-K for the year ended March 31, 2025 and in our other filings with the Securities and Exchange Commission. These risks and uncertainties include: our reliance on a small number of significant customers; continued vertical integration by our customers; global shifts in sourcing customer requirements, the imposition of tariffs and other changes in international trade policies; shifts in the global supply and demand position for tobacco products; variation in our financial results due to growing conditions, customer indications and other factors; loss of confidence in us by our customers, farmers and other suppliers; migration of suppliers who have historically grown tobacco and from whom we have purchased tobacco toward growing other crops; risks related to our advancement of inputs to tobacco suppliers to be settled upon the suppliers delivering us unprocessed tobacco at the end of the growing season; risks that the tobacco we purchase directly from suppliers will not meet our customers' quality and quantity requirements; weather and other environmental conditions that can affect the quantity and marketability of our inventory; international business risks, including unsettled political conditions, uncertainty in the enforcement of legal obligations, including the collection of accounts receivable, fraud risks, expropriation, import and export restrictions, exchange controls, inflationary economies, currency risks and risks related to the restrictions on repatriation of earnings or proceeds from liquidated assets of foreign subsidiaries; many of our operations are located in jurisdictions that pose a high risk of potential violations of the Foreign Corrupt Practices Act; risks and uncertainties related to geopolitical conflicts, including the conflicts in the Middle East and disruptions affecting shipping in that area; impacts of international sanctions on our ability to sell or source tobacco in certain regions; exposure to foreign tax regimes in which the rules are not clear, are not consistently applied and are subject to sudden change; fluctuations in foreign currency exchange and interest rates; competition with the other primary global independent leaf tobacco merchant and independent leaf merchants; disruption, failure or security breaches of our information technology systems and other cybersecurity risks; continued high inflation; regulations regarding environmental matters; risks related to our capital structure, including risks related to our significant debt and our ability to continue to finance our non-U.S. local operations with uncommitted short-term operating credit lines at the local level; our ability to continue to access capital markets to obtain long-term and short-term financing; potential failure of foreign banks in which our subsidiaries maintain deposits or the failure by such banks to transfer funds or honor withdrawals; the risk that, because our ability to generate cash depends on many factors beyond our control, we may be unable to generate the significant amount of cash required to service our indebtedness; our ability to refinance our current credit facilities at the same availability or at similar or reduced interest rates; failure to achieve our stated goals, which may adversely affect our liquidity; developments with respect to our liquidity needs and sources of liquidity; the volatility and disruption of global credit markets; failure by counterparties to derivative transactions to perform their obligations; increasing scrutiny and changing expectations from governments, as well as other stakeholders such as investors and customers, with respect to our environmental, social and governance policies, including sustainability policies; inherent risk of exposure to product liability claims, regulatory action and litigation facing our e-liquids business if its products are alleged to have caused significant loss, injury, or death; certain shareholders have the ability to exercise controlling influence on various corporate matters; reductions in demand for consumer tobacco products; risks and uncertainties related to pandemics or other widespread health crises and any related shipping constraints, labor shortages and supply-chain impacts; legislative and regulatory initiatives that may reduce consumption of consumer tobacco products and demand for our services and increase regulatory burdens on us or our customers; government actions that significantly affect the sourcing of tobacco, including governmental actions to identify and assess crop diversification initiatives and alternatives to leaf tobacco growing in countries whose economies depend upon tobacco production; governmental investigations into the Company's business activities, including but not limited to, leaf tobacco industry buying and other payment practices; and impact of proposed regulations to prohibit the sale of cigarettes and certain other tobacco products in the United States other than low-nicotine versions of those products.

We do not undertake to update any forward-looking statements that we may make from time to time except to the extent required by law.

***Overview***

Pyxus is a global agricultural company with businesses having more than 150 years of experience delivering value-added products and services to businesses and customers. The Company is a trusted provider of responsibly sourced, independently verified, sustainable, and traceable products and ingredients.

------

***Executive Summary***

The start to fiscal year 2026 delivered a larger tobacco crop than we experienced in the prior year, and we are pleased with our ability to capture larger quantities of leaf in key markets. As anticipated, first quarter results were below the same period of the prior year as a result of the acceleration of certain customer shipments into the fourth quarter of fiscal year 2025. Despite a 19.9% reduction in sales and other operating revenues to $508.8 million during the three months ended June 30, 2025 from $634.9 million during the three months ended June 30, 2024, the Company's gross margin as a percent of sales remained relatively stable over the same period due mainly to product mix.

Crop purchases in the Southern hemisphere are near completion and have been strong to date as favorable weather conditions have produced larger volumes of better quality leaf when compared to the prior year, which is evident in both Africa and South America, where unfavorable weather conditions dampened the prior-year crop. Our strengthened credit profile enabled us to secure the necessary funds to purchase these larger volumes of green tobacco to satisfy demand from our customers. Our total tobacco inventory balance, comprised of both processed and unprocessed tobacco, of $1,089.8 million at June 30, 2025, puts us in the position to meet the needs of our customers.

------

**Results of Operations**

---

| | | | |
|:---|:---|:---|:---|
| ***Three Months Ended June 30, 2025 and 2024*** | ***Three Months Ended June 30, 2025 and 2024*** | ***Three Months Ended June 30, 2025 and 2024*** | ***Three Months Ended June 30, 2025 and 2024*** |
|  | Three Months Ended June 30, | Three Months Ended June 30, | Three Months Ended June 30, |
|  |  |  | Change |
| *(in millions, except per kilo amounts)* | 2025 | 2024 | $% |
| Consolidated: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and other operating revenues | $508.8 | $634.9 | (19.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods and services sold | 443.2 | 551.0 | (19.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 65.6 | 83.9 | (21.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit as a percent of sales | 12.9% | 13.2% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative expenses | $40.4 | $40.7 | (0.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other expense, net | 4.2 | 2.6 | 61.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset impairment charges | 0.1 | 0.1 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income\* | 21.0 | 40.5 | (48.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on debt retirement |  | 1.3 | (100.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 29.8 | 33.3 | (10.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loss) income before income taxes and other items | (8.8) | 8.5 | (203.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 5.2 | 6.1 | (14.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) income from unconsolidated affiliates, net | (1.3) | 2.6 | (150.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to noncontrolling interests | 0.6 | 0.3 | 100.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income attributable to Pyxus International, Inc.\* | $(15.8) | $4.6 | (443.5) |
| Leaf: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Product revenues | $458.2 | $589.2 | (22.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Tobacco costs | 375.7 | 484.0 | (22.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Transportation, storage, and other period costs | 25.1 | 24.8 | 1.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total product cost of goods sold | 400.8 | 508.8 | (21.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Product gross profit | 57.4 | 80.4 | (28.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Product gross profit as a percent of sales | 12.5% | 13.6% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Kilos sold | 66.9 | 95.7 | (30.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Average price per kilo | $6.85 | $6.16 | 11.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Average cost per kilo | 5.99 | 5.32 | 12.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Average gross profit per kilo | 0.86 | 0.84 | 2.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Processing and other revenues | $50.2 | $41.8 | 20.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Processing and other costs of services sold | 42.6 | 37.4 | 13.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Processing and other gross profit | 7.6 | 4.4 | 72.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Processing and other gross profit as a percent of sales | 15.1% | 10.5% |  |
| All Other: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and other operating revenues | $0.4 | $3.9 | (89.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods and services sold | (0.2) | 4.8 | (104.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit (loss) | 0.6 | (0.9) | 166.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit (loss) as a percent of sales | 150.0% | (23.1)% |  |
| *\* Amounts may not equal column totals due to rounding.* | *\* Amounts may not equal column totals due to rounding.* | *\* Amounts may not equal column totals due to rounding.* | *\* Amounts may not equal column totals due to rounding.* |

---

------

Sales and other operating revenues decreased $126.1 million, or 19.9%, to $508.8 million for the three months ended June 30, 2025 from $634.9 million for the three months ended June 30, 2024. This decline was a result of a 30.1% decrease in kilo volumes sold primarily from Africa and North America due to the timing of certain customer shipments. In the fourth quarter of fiscal year 2025, certain customer orders were accelerated from Africa and North America, which resulted in the year-over-year sales decline that was partially offset by higher average sales prices.

Cost of goods and services sold decreased $107.8 million, or 19.6%, to $443.2 million for the three months ended June 30, 2025 from $551.0 million for the three months ended June 30, 2024. This decrease was mainly due to the reduction in sales and other operating revenues.

Gross profit as a percent of sales decreased to 12.9% for the three months ended June 30, 2025 from 13.2% for the three months ended June 30, 2024. The slight decline was driven by regional and customer sales mix within leaf, partially offset by an increase in processing and other gross profit.

------

**Liquidity and Capital Resources**

***Overview***

Our primary sources of liquidity are cash generated from operations, short-term borrowings under our foreign seasonal lines of credit, availability under our ABL Credit Facility, and cash collections from our securitized receivables. Our liquidity requirements are affected by various factors from our core tobacco leaf business, including crop seasonality, foreign currency and interest rates, green tobacco prices, customer mix, crop size, and quality. Our leaf tobacco business is seasonal, and purchasing, processing, and selling activities have several associated peaks where cash on-hand and outstanding indebtedness may vary significantly compared to year end. The first three quarters of our fiscal year generally represent the peak of our working capital requirements.

Although we believe that our sources of liquidity will be sufficient to fund our anticipated operating needs for the next twelve months, we anticipate periods during which our liquidity needs for operations will approach the levels of our anticipated available cash and permitted borrowings under our credit facilities. Unanticipated developments affecting our liquidity needs, including with respect to the foregoing factors, and sources of liquidity, including impacts affecting our cash flows from operations and the availability of capital resources (including an inability to renew or refinance seasonal lines of credit), may result in a deficiency in liquidity. To address a potential liquidity deficiency, we may undertake plans to minimize cash outflows, which could include exiting operations that do not generate positive cash flow. It is possible that, depending on the occurrence of events affecting our liquidity needs and sources of liquidity, such plans may not be sufficient to adequately or timely address a liquidity deficiency.

***Debt Financing***

We continue to finance our business with a combination of short-term and long-term credit lines, the long-term debt securities, advances from customers, and cash from operations when available. See "<u>[Note 11. Debt Arrangements](#i2474226e74764caf8765b48a7e12feb1_73)</u>" to the "Notes to Condensed Consolidated Financial Statements" for a summary of our short-term and long-term debt.

We continuously monitor and, as available, adjust funding sources as needed to enhance and drive various business opportunities. From time to time we may take steps to reduce our debt or otherwise improve our financial position. Such actions could include prepayments, open market debt repurchases, negotiated repurchases, other redemptions or retirements of outstanding debt, and refinancing of debt. The amount of prepayments or the amount of debt that may be repurchased, refinanced, or otherwise retired, if any, will depend on market conditions, trading levels of our debt, our cash position, compliance with debt covenants, and other considerations.

The following summarizes our total borrowing capacity at June 30, 2025 and 2024 under our short-term and long-term credit lines and letter of credit facilities and the remaining available amount after the reduction for outstanding borrowings and amounts reserved for outstanding letters of credit:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | June 30, 2025 | June 30, 2025 | June 30, 2024 | June 30, 2024 |
| *(in millions)* | Total Borrowing Capacity | Remaining Amount Available | Total Borrowing Capacity | Remaining Amount Available |
| Senior Secured Credit Facilities: |  |  |  |  |
| &nbsp;&nbsp;ABL Credit Facility | $150.0 | $150.0 | $120.0 | $76.0 |
| Foreign seasonal lines of credit | 1025.2 | 171.2 | 815.6 | 169.7 |
| Other long-term debt |  |  | 0.4 | 0.3 |
| Letters of credit | 12.3 | 3.4 | 10.6 | 2.9 |
| &nbsp;&nbsp;Total | $1187.5 | $324.6 | $946.6 | $248.9 |

---

The total borrowing capacity under the ABL Credit Facility increased $30.0 million when compared to the prior period as a result of the Fourth Amendment to the ABL Credit Agreement entered into on May 12, 2025, which among other things, increased the aggregate amount of revolving loan commitments from $120.0 million to $150.0 million. The amounts presented as available under the ABL Credit Facility are subject to further limitations from the borrowing base consisting of certain eligible accounts receivable and inventory, reduced by specified reserves.

The total borrowing capacity of our foreign seasonal lines of credit increased $209.6 million when compared to the prior year and were primarily utilized to purchase larger volumes of green tobacco. The amounts presented as the remaining amount available for borrowing under the foreign seasonal lines of credit are subject to limitations based on the level of receivables and inventories as collateral and by certain restrictive covenants.

------

***Net Debt***

We refer to "Net debt," a non-GAAP measure, as total debt liabilities less cash and cash equivalents. We believe this non-GAAP financial measure is useful to monitor leverage and to evaluate changes to the Company's capital structure. A limitation associated with using net debt is that it subtracts cash and cash equivalents, and therefore, may imply that management intends to use cash and cash equivalents to reduce outstanding debt and that cash held in certain jurisdictions can be applied to repay obligations owing in other jurisdictions and without reduction for applicable taxes. In addition, net debt suggests that our debt obligations are less than the most comparable GAAP measure indicates. The following summarizes the computation of net debt:

---

| | | | |
|:---|:---|:---|:---|
| *(in millions)* | June 30, 2025 | June 30, 2024 | March 31, 2025 |
| Notes payable | $880.9 | $679.4 | $395.0 |
| Current portion of long-term debt |  | 20.4 |  |
| Long-term debt<sup>(1)</sup> | 455.1 | 531.5 | 454.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total debt liabilities | $1336.0 | $1231.3 | $849.9 |
| Less: Cash and cash equivalents | 96.4 | 82.0 | 78.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net debt | $1239.6 | $1149.3 | $771.6 |
| <sup>(1)</sup> Fluctuations in long-term debt include borrowings and repayments on the outstanding indebtedness under the ABL Credit Facility, along with repurchases of certain long-term debt. Weighted average borrowings outstanding under the ABL Credit Facility were $57.6 million for the three months ended June 30, 2025. | <sup>(1)</sup> Fluctuations in long-term debt include borrowings and repayments on the outstanding indebtedness under the ABL Credit Facility, along with repurchases of certain long-term debt. Weighted average borrowings outstanding under the ABL Credit Facility were $57.6 million for the three months ended June 30, 2025. | <sup>(1)</sup> Fluctuations in long-term debt include borrowings and repayments on the outstanding indebtedness under the ABL Credit Facility, along with repurchases of certain long-term debt. Weighted average borrowings outstanding under the ABL Credit Facility were $57.6 million for the three months ended June 30, 2025. | <sup>(1)</sup> Fluctuations in long-term debt include borrowings and repayments on the outstanding indebtedness under the ABL Credit Facility, along with repurchases of certain long-term debt. Weighted average borrowings outstanding under the ABL Credit Facility were $57.6 million for the three months ended June 30, 2025. |

---

Net debt increased as of June 30, 2025 when compared to June 30, 2024 due to higher borrowings on our foreign seasonal lines of credit, partially offset by lower borrowings on the ABL Credit Facility and the repurchase of certain long-term debt in August 2024.

***Working Capital***

The following summarizes our working capital:

---

| | | | |
|:---|:---|:---|:---|
| *(in millions except for current ratio)* | June 30, 2025 | June 30, 2024 | March 31, 2025 |
| Cash, cash equivalents, and restricted cash | $101.4 | $89.1 | $85.5 |
| Trade and other receivables, net | 223.3 | 226.1 | 204.3 |
| Inventories and advances to tobacco suppliers, net | 1183.5 | 1058.4 | 792.7 |
| Recoverable income taxes | 11.7 | 4.1 | 6.6 |
| Prepaid expenses and other current assets | 71.1 | 64.5 | 69.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets\* | $1591.0 | $1442.1 | $1158.2 |
| Notes payable | $880.9 | $679.4 | $395.0 |
| Accounts payable | 124.3 | 115.3 | 132.9 |
| Advances from customers | 87.4 | 71.0 | 135.6 |
| Accrued expenses and other current liabilities | 104.2 | 99.1 | 90.9 |
| Income taxes payable | 10.4 | 8.7 | 11.0 |
| Operating leases payable | 9.6 | 7.8 | 8.5 |
| Current portion of long-term debt |  | 20.4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | $1216.8 | $1001.7 | $773.9 |
| Current ratio | 1.3 to 1 | 1.4 to 1 | 1.5 to 1 |
| Working capital | $374.2 | $440.4 | $384.3 |
| *\* Amounts may not equal column totals due to rounding* | *\* Amounts may not equal column totals due to rounding* |  |  |

---

Working capital declined from June 30, 2024 to June 30, 2025 by $66.2 million, or 15.0%, driven by higher borrowings on our foreign seasonal lines of credit to fund the purchases of larger volumes of green tobacco, particularly in Africa and South America.

------

***Inventories***

The following summarizes inventory committed to a customer and uncommitted inventory balances for processed tobacco:

---

| | | | |
|:---|:---|:---|:---|
| *(in millions)* | June 30, 2025 | June 30, 2024 | March 31, 2025 |
| Committed | $562.3 | $590.8 | $482.8 |
| Uncommitted | 13.6 | 14.7 | 7.6 |
| &nbsp;&nbsp;Total processed tobacco | $575.9 | $605.5 | $490.4 |

---

Total processed tobacco decreased from June 30, 2024 to June 30, 2025 by $29.6 million, or 4.9%, primarily from lower inventory costs of the current crop that has been processed in South America. Uncommitted levels of processed tobacco remain low due to strong demand from our customers. While undersupply conditions have persisted in the global tobacco market in recent periods, the larger crops experienced in Africa and South America are anticipated to provide a more balanced position. See "<u>[Note 7. Inventories, Net](#i2474226e74764caf8765b48a7e12feb1_61)</u>" to the "Notes to Condensed Consolidated Financial Statements" for additional information.

***Sources and Uses of Cash***

We typically finance our non-U.S. tobacco operations with committed and uncommitted short-term foreign seasonal lines of credit, normally extending for a term of 180 to 365 days, corresponding to the tobacco crop cycle in that market. For uncommitted facilities, the lenders have the right to cease making loans and demand repayment of loans. These short-term seasonal lines of credit are generally renewed at the outset of each tobacco season. We maintain various other financing arrangements to meet the cash requirements of our businesses. See "<u>[Note 11. Debt Arrangements](#i2474226e74764caf8765b48a7e12feb1_73)</u>" to the "Notes to Condensed Consolidated Financial Statements" for additional information.

We utilize capital in excess of cash flow from operations to finance accounts receivable, inventory, and advances to tobacco suppliers in foreign countries. In addition, we may periodically elect to purchase, redeem, repay, retire, or cancel indebtedness prior to stated maturity under our various foreign credit lines.

As of June 30, 2025, our cash, cash equivalents, and restricted cash was $101.4 million, of which approximately $79.1 million was held in non-U.S. jurisdictions for non-U.S. working capital needs, a majority of which is subject to exchange controls and a portion of which is subject to tax consequences upon repatriation, which could limit our ability to fully repatriate these funds. Fluctuation of the U.S. dollar versus many of the currencies in which we have costs may have an impact on our working capital requirements. We will continue to monitor and hedge foreign currency costs, as needed.

------

The following summarizes the sources and uses of our cash flows:

---

| | | |
|:---|:---|:---|
| | Three Months Ended | Three Months Ended |
| | June 30, | June 30, |
| *(in millions)* | 2025 | 2024 |
| Net (loss) income | $(15.3) | $5.0 |
| Inventories and advances to tobacco suppliers | (388.0) | (108.0) |
| Payables and accrued expenses | 0.4 | (64.8) |
| Advances from customers | (49.8) | (18.6) |
| Other | (42.6) | (65.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | $(495.3) | $(252.2) |
| Collections from beneficial interests in securitized trade receivables | 41.0 | 31.7 |
| Other | (3.4) | (3.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by investing activities | $37.6 | $27.9 |
| Net proceeds from short-term borrowings | 476.9 | 182.0 |
| Net proceeds from revolving loan facilities |  | 44.0 |
| Repayment of long-term borrowings |  | (9.1) |
| Other | (2.4) | (2.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | $474.5 | $214.3 |
| Effect of exchange rate changes on cash | (1.0) | (0.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in cash, cash equivalents, and restricted cash\* | $15.8 | $(10.7) |
| *\* Amounts may not equal column totals due to rounding* | *\* Amounts may not equal column totals due to rounding* |  |

---

The change in cash, cash equivalents, and restricted cash for the three months ended June 30, 2025 compared to the three months ended June 30, 2024 increased by $26.5 million. This increase was driven by higher net proceeds received from foreign seasonal lines of credit, partially offset by an increase in cash used in operations to fund purchases of larger crops.

*Planned Capital Expenditures*

Capital investments in our leaf operations were primarily for routine replacement of machinery and equipment, as well as investments in assets to enhance our sustainability efforts or increase efficiencies, which we believe will add value to our customers. We incurred approximately $4.3 million in capital expenditures for the three months ended June 30, 2025, and are expecting to incur an additional $21.8 million for the remainder of the fiscal year ending March 31, 2026.

*Pension and Postretirement Health and Life Insurance Benefits*

The following summarizes cash contributions to pension and postretirement health and life insurance benefits:

---

| | |
|:---|:---|
| | Three Months Ended |
| *(in millions)* | June 30, 2025 |
| Contributions made during the period | $1.1 |
| Contributions expected for the remainder of the fiscal year | 3.4 |
| &nbsp;&nbsp;Total | $4.5 |

---

**Critical Accounting Estimates**

There have been no material changes to our critical accounting estimates since March 31, 2025. For information regarding our critical accounting estimates, see Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2025.

**<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>**

There have been no material changes to our market risk exposures since March 31, 2025. For a discussion of our exposure to market risk, see Part II, Item 7A "Quantitative and Qualitative Disclosures About Market Risk" contained in our Annual Report on Form 10-K for the fiscal year ended March 31, 2025.

------

**<u>Item 4. Controls and Procedures</u>**

**Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) designed to provide reasonable assurance that the information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that this information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. Due to inherent limitations, our disclosure controls and procedures, however well designed and operated, can provide only reasonable assurance (not absolute) that the objectives of the disclosure controls and procedures are met.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as required by Rule 13a-15(b) of the Exchange Act) as of June 30, 2025. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) were effective to provide reasonable assurance as of June 30, 2025.

**Changes in Internal Control over Financial Reporting**

As required by Rule 13a-15(d) under the Exchange Act, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that no changes in our internal control over financial reporting occurred during the three months ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**Part II. Other Information**

**<u>Item 1. Legal Proceedings</u>** 

See "<u>[Note 16. Contingencies and Other Information](#i2474226e74764caf8765b48a7e12feb1_91)"</u> to the "Notes to Condensed Consolidated Financial Statements" for additional information with respect to legal proceedings, which are incorporated by reference herein.

**<u>Item 1A. Risk Factors</u>**

In addition to the other information set forth in this report and in our other filings with the Securities and Exchange Commission, investors should carefully consider our risk factors, which could materially affect our business, financial condition, or operating results. As of the date of this report, there are no material changes or updates to the risk factors previously disclosed in Part I, Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2025.

**<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>**

**Issuer Purchases of Equity Securities**

The Company did not repurchase any of its equity securities during the three months ended June 30, 2025.

On August 15, 2024, the Board of Directors authorized a program to repurchase up to $10,000,000 plus fees and expenses of our common stock in the open market or through privately negotiated transactions, subject to limitations under the Company's debt agreements (which currently limit the aggregate amount that may be applied to repurchase shares of common stock to $1,000,000). The repurchase by the Company on August 21, 2024 of shares of its common stock for approximately $1,000,000, inclusive of brokerage fees, was applied to this limit. This program expires on August 15, 2027. If current restrictions under applicable debt agreements are modified to permit further repurchases of common stock by the Company, the number, price, structure and timing of any further share repurchases will be at the Company's sole discretion, and any such future repurchases of our common stock are dependent on market conditions, liquidity needs, and certain restrictions under our debt arrangements, among other factors.

No cash dividends on shares of common stock of Pyxus International, Inc. were paid to shareholders during the three months ended June 30, 2025. As of June 30, 2025, the payment of such dividends is restricted under the terms of our debt agreements.

------

**<u>Item 5. Other Information</u>**

During the three months ended June 30, 2025, none of the Company's directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a "Rule 10b5-1 trading arrangement" or adopted or terminated a "non-Rule 10b5-1 trading arrangement" (as such terms are defined in Item 408 of Regulation S-K).

**<u>Item 6. Exhibits</u>**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| <u>[10.1](https://www.sec.gov/Archives/edgar/data/939930/000093993025000025/exhibit101fourthamendmentt.htm)</u> | Fourth Amendment to ABL Credit Agreement dated as of May 12, 2025 by and among Pyxus Holdings, Inc., the other borrowers and guarantors party thereto, the lenders party thereto and PNC Bank, National Association, as administrative agent and collateral agent, incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on May 13, 2025 (File No. 000-25734). |
| <u>[31.1](pyx-2025x06x30xex311.htm)</u> | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith) |
| <u>[31.2](pyx-2025x06x30xex312.htm)</u> | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith) |
| <u>[32](pyx-2025x06x30xex32.htm)</u> | Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith) |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document (filed herewith) |
| 101.SCH | Inline XBRL Taxonomy Extension Schema (filed herewith) |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase (filed herewith) |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase (filed herewith) |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase (filed herewith) |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase (filed herewith) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

---

------

---

| | |
|:---|:---|
| **SIGNATURE** | **SIGNATURE** |
| &nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. | &nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. |
|  | Pyxus International, Inc. |
| Date: August 6, 2025 | /s/ Christopher G. Meredith |
|  | Christopher G. Meredith |
|  | Corporate Controller |
|  | (Principal Accounting Officer) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION**

I, J. Pieter Sikkel, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of Pyxus International, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| /s/ J. Pieter Sikkel |
| J. Pieter Sikkel&nbsp;&nbsp;&nbsp;&nbsp;<br>President and Chief Executive Officer |
| August 6, 2025 |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION**

I, Dustin L. Styons, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of Pyxus International, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| /s/ Dustin L. Styons |
| Dustin L. Styons<br>Executive Vice President and Chief Financial Officer |
| August 6, 2025 |

---

## Ex-32

**Exhibit 32**

**CERTIFICATION PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

In connection with the Quarterly Report on Form 10-Q of Pyxus International, Inc. (the "Company") for the period ended June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned officers hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), to their knowledge, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 6, 2025

---

| |
|:---|
| /s/ J. Pieter Sikkel |
| J. Pieter Sikkel&nbsp;&nbsp;&nbsp;&nbsp;<br>President and Chief Executive Officer |
| /s/ Dustin L. Styons |
| Dustin L. Styons<br>Executive Vice President and Chief Financial Officer |

---

<br>